Bristol-Myers (BMY), Pfizer (PFE) Tick Higher; ELIQUIS NDA Accepted for Review
Tweet
Share
E-mailGet Alerts BMY Hot Sheet
Price: $67.66 +1.11%
Overall Analyst Rating:
SELL (= Flat)
Dividend Yield: 4.5%
Revenue Growth %: +3.2%
Overall Analyst Rating:
SELL (= Flat)
Dividend Yield: 4.5%
Revenue Growth %: +3.2%
Join SI Premium – FREE
Bristol-Myers Squibb Company (NYSE: BMY) and Pfizer Inc. (NYSE: PFE) are trading a little higher early Tuesday, following reports that the U.S. FDA accepted a New Drug Application (NDA) for ELIQUIS (apixaban) for review.
Bristol is up about 0.4 percent, while Pfizer is 1 percent stronger.
Click here for more.
Bristol is up about 0.4 percent, while Pfizer is 1 percent stronger.
Click here for more.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- BMS presents five-year Camzyos data for heart condition at ESC
- Agencia awards MEP contracts for Indonesia data center Phase 1A
- Bausch + Lomb publishes real-world study on enVista Aspire lenses
Create E-mail Alert Related Categories
FDA, Insiders' BlogSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
